ASSENT-3: implications for future trial design and clinical practice

Eur Heart J. 2002 Jun;23(12):911-2. doi: 10.1053/euhj.2001.3048.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Clinical Protocols / standards
  • Clinical Trials, Phase II as Topic
  • Controlled Clinical Trials as Topic*
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Myocardial Infarction / drug therapy
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use
  • Research Design / trends*
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Tissue Plasminogen Activator